EP1311548A4 - T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders - Google Patents

T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders

Info

Publication number
EP1311548A4
EP1311548A4 EP01939376A EP01939376A EP1311548A4 EP 1311548 A4 EP1311548 A4 EP 1311548A4 EP 01939376 A EP01939376 A EP 01939376A EP 01939376 A EP01939376 A EP 01939376A EP 1311548 A4 EP1311548 A4 EP 1311548A4
Authority
EP
European Patent Office
Prior art keywords
treatment
cell binding
binding ligand
constructs containing
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01939376A
Other languages
German (de)
French (fr)
Other versions
EP1311548A1 (en
Inventor
Daniel S Zimmerman
Prem S Sarin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cel Sci Corp
Original Assignee
Cel Sci Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cel Sci Corp filed Critical Cel Sci Corp
Publication of EP1311548A1 publication Critical patent/EP1311548A1/en
Publication of EP1311548A4 publication Critical patent/EP1311548A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP01939376A 2000-05-24 2001-05-24 T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders Withdrawn EP1311548A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20654800P 2000-05-24 2000-05-24
US206548P 2000-05-24
PCT/US2001/016793 WO2001089286A2 (en) 2000-05-24 2001-05-24 T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders

Publications (2)

Publication Number Publication Date
EP1311548A1 EP1311548A1 (en) 2003-05-21
EP1311548A4 true EP1311548A4 (en) 2005-01-19

Family

ID=22766866

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939376A Withdrawn EP1311548A4 (en) 2000-05-24 2001-05-24 T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders

Country Status (4)

Country Link
EP (1) EP1311548A4 (en)
JP (1) JP2003533542A (en)
AU (1) AU2001264902A1 (en)
WO (1) WO2001089286A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108342405A (en) * 2017-01-23 2018-07-31 复旦大学 IL21 fusion proteins and preparation method thereof and the purposes in preparing targeting therapy on tumor drug
EP3768699A1 (en) * 2018-03-23 2021-01-27 Gavish-Galilee Bio Applications, Ltd Genetically reprogrammed tregs expressing membrane-bound il-10

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006429A1 (en) * 1996-08-09 1998-02-19 Viral Technologies, Inc. Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
WO1998006416A1 (en) * 1996-08-09 1998-02-19 Cel-Sci Corporation Conjugated peptides, immunological reagent containing same and use thereof for treatment of immunological disorders
WO2001036448A2 (en) * 1999-10-27 2001-05-25 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006429A1 (en) * 1996-08-09 1998-02-19 Viral Technologies, Inc. Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
WO1998006416A1 (en) * 1996-08-09 1998-02-19 Cel-Sci Corporation Conjugated peptides, immunological reagent containing same and use thereof for treatment of immunological disorders
WO2001036448A2 (en) * 1999-10-27 2001-05-25 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHAROENVIT Y ET AL: "CEL-1000-a peptide with adjuvant activity for Th1 immune responses", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 19, 23 June 2004 (2004-06-23), pages 2368 - 2373, XP004515451, ISSN: 0264-410X *
PISAREV V M ET AL: "Enhanced immunogenicity of an HIV gag peptide by conjugation to MHCIIbeta2 or IL-1beta epitopes is augmented, with type 1 T-cell responses, by Flt3 ligand", FASEB JOURNAL, vol. 14, no. 6, 20 April 2000 (2000-04-20), & JOINT ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE CLINICAL IMMUNOLOGY SOCIET; SEATTLE, WASHINGTON, USA; MAY 12-16, 2000, pages A943, XP009040567, ISSN: 0892-6638 *
WANG R ET AL: "Protective immunity against malaria by immunization with PYSSP2 CD4+ T helper epitope conjugated to MHC class II binding ligand MHC-II beta-chain peptide 135-149", AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 62, no. 3 Supplement, March 2000 (2000-03-01), & 49TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE; HOUSTON, TEXAS, USA; OCTOBER 29-NOVEMBER 02, 2000, pages 331 - 332, XP009040577, ISSN: 0002-9637 *
ZIMMERMAN D H ET AL: "Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1SF2 p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 32, 14 September 2001 (2001-09-14), pages 4750 - 4759, XP004303170, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2001089286A2 (en) 2001-11-29
JP2003533542A (en) 2003-11-11
AU2001264902A1 (en) 2001-12-03
EP1311548A1 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
HUP0003533A3 (en) Interleukin-18 binding proteins, their preparation and use
IL158126A0 (en) Peptides and antibodies to muc 1 proteins
AU2002365396A8 (en) Peptides, peptide compositions,and methods of use in binding p 185
HUP0600335A2 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
IL153539A0 (en) Protein complexes and methods for the preparation thereof
AU2001232833A1 (en) Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
GB2321191B (en) Peptides for use in wound treatment
EP1276757A4 (en) ANTIGENIC PEPTIDE FRAGMENTS OF VapA PROTEIN, AND USES THEREOF
EP1186615A4 (en) Novel protein and dna thereof
EP1210110A4 (en) Prion protein binding proteins and uses thereof
EP1194548A4 (en) Novel pyrrhocoricin-derived peptides, and methods of use thereof
AU2001245896A1 (en) Maize glycine rich protein promoter compositions and methods for use thereof
EP1311548A4 (en) T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders
GB9918155D0 (en) Proteins and peptides
EP1293568A4 (en) Novel protein and dna thereof
EP0966296A4 (en) Conjugated peptides, immunological reagent containing same and use thereof for treatment of immunological disorders
AU2001291994A1 (en) Dipeptide ligands of the npff receptor for treating pain and hyperalgesia
GB0030309D0 (en) Antibodies,Peptides,Analogs and uses thereof
EP1283870A4 (en) Novel cell systems having specific interaction of peptide binding pairs
AU2002221428A1 (en) Novel polypeptide human polyadenylation binding protein 20.13 and polynucleotideencoding it
HUP0103384A3 (en) Novel peptides for use in immunotherapy of autoimmune diseases
EP1293510A4 (en) Novel polypeptide and its dna
EP1302477A4 (en) Peptide fructose and complex thereof with binding protein
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
EP1084235A4 (en) Human protein c polypeptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021223

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041206

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12P 21/08 B

Ipc: 7C 12N 15/00 B

Ipc: 7C 07K 19/00 B

Ipc: 7C 07K 14/00 B

Ipc: 7C 07K 7/08 B

Ipc: 7A 61P 37/04 B

Ipc: 7A 61P 31/18 B

Ipc: 7A 61K 39/39 B

Ipc: 7A 61K 39/21 B

Ipc: 7A 61K 39/00 B

Ipc: 7C 07K 14/16 B

Ipc: 7C 07K 16/00 A

17Q First examination report despatched

Effective date: 20060814

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090214